PRESS RELEASE published on 12/24/2024 at 20:46, 1 year 8 months ago Informations privilégiées / Autres communiqués GenSight Biologics annonce un financement de 1,5 million d'euros auprès d'investisseurs existants pour le développement de thérapies géniques innovantes. Perspectives de croissance et objectifs à court terme Croissance Financement Investisseurs GenSight Biologics Thérapies Géniques
BRIEF published on 11/13/2024 at 07:35, 1 year 9 months ago GenSight Biologics Submits LUMEVOQ® Dossier to ANSM Gene Therapy GenSight Biologics Early Access Program Leber Hereditary Optic Neuropathy Regulatory Submission
BRIEF published on 11/13/2024 at 07:35, 1 year 9 months ago GenSight Biologics dépose le dossier LUMEVOQ® auprès de l'ANSM Thérapie Génique GenSight Biologics Programme D'accès Anticipé Neuropathie Optique Héréditaire De Leber Soumission Réglementaire
PRESS RELEASE published on 11/13/2024 at 07:30, 1 year 9 months ago Inside Information / Other news releases GenSight Biologics submits updated LUMEVOQ Dossier to ANSM for early access program restart in France to treat LHON, aiming for first injections in December 2024 GenSight Biologics LHON LUMEVOQ Early Access Program ANSM
PRESS RELEASE published on 11/13/2024 at 07:30, 1 year 9 months ago Informations privilégiées / Autres communiqués GenSight Biologics soumet le dossier de LUMEVOQ® à l'ANSM pour reprendre le programme d'accès compassionnel en France. Premieres injections prévues en décembre 2024 Thérapie Génique GenSight Biologics LUMEVOQ ANSM Neuropathie Optique
BRIEF published on 11/01/2024 at 18:23, 1 year 10 months ago GenSight Biologics Secures €2.8 Million Financing Warrants Financing Gene Therapy GenSight Biologics Retinal Diseases
BRIEF published on 11/01/2024 at 18:23, 1 year 10 months ago GenSight Biologics obtient un financement de 2,8 millions d'euros Financement Thérapie Génique Mandats GenSight Biologics Maladies De La Rétine
PRESS RELEASE published on 11/01/2024 at 18:18, 1 year 10 months ago Inside Information / Other news releases GenSight Biologics announces a €2.8 million financing through a Reserved Offering. Funding to extend cash runway for developing gene therapies. Details on investor support and future plans Investors Financing GenSight Biologics Gene Therapies Reserved Offering
PRESS RELEASE published on 11/01/2024 at 18:18, 1 year 10 months ago Informations privilégiées / Autres communiqués GenSight Biologics annonce un financement de 2,8 millions d’euros auprès d’investisseurs existants pour soutenir le développement de thérapies géniques innovantes Développement Financement Investisseurs GenSight Biologics Thérapies Géniques
BRIEF published on 10/24/2024 at 21:13, 1 year 10 months ago GenSight Biologics dévoile sa situation de trésorerie et avance sur le LUMEVOQ® Financement Trésorerie LUMEVOQ® Accès Compassionnel ANSM
Published on 09/10/2026 at 22:25, 4 hours 25 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 11 hours 30 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 11 hours 50 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/10/2026 at 14:37, 12 hours 13 minutes ago Worksport (NASDAQ:WKSP) Invites Shareholders to September 15 CEO Town Hall
Published on 09/11/2026 at 00:05, 2 hours 45 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/11/2026 at 00:01, 2 hours 49 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/10/2026 at 22:39, 4 hours 11 minutes ago EQS-Adhoc: Notice by Rumble Deutschland AG regarding an upcoming squeeze-out under German Stock Corporation Law
Published on 09/10/2026 at 22:10, 4 hours 40 minutes ago flatexDEGIRO with changes to the Supervisory Board
Published on 09/10/2026 at 22:07, 4 hours 43 minutes ago EQS-Adhoc: flatexDEGIRO SE: Changes to the Supervisory Board
Published on 09/10/2026 at 19:30, 7 hours 20 minutes ago Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 19:30, 7 hours 20 minutes ago Mise à disposition du Rapport Financier Semestriel 2026
Published on 09/10/2026 at 18:10, 8 hours 40 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 août 2026
Published on 09/10/2026 at 17:45, 9 hours 5 minutes ago COGRA : RÉSULTATS ANNUELS 2025/26 - Retour à la croissance rentable et structure financière renforcée
Published on 09/10/2026 at 17:42, 9 hours 8 minutes ago Déclaration d'actions et de droits de vote au 31.08.2026
